
Advanced Regenerative Bio Act
Korea’s main law on regenerative treatments that use human cells, and on medicines made from cells, genes or engineered tissue.
The Advanced Regenerative Bio Act sets the rules for treatments and research that use human cells, genes or engineered tissue, and for advanced biopharmaceuticals such as cell therapy products.
Since 21 February 2025, Korea allows advanced regenerative therapy only at institutions designated by the Ministry of Health and Welfare, under a treatment plan approved by a review committee, for patient groups defined by law. Purely cosmetic use is not allowed. The Act also bans false or exaggerated advertising about the effects of these treatments and about how cells are stored.
Practical check: ask the clinic in writing which legal route your treatment is offered under. If it is this Act, ask whether the clinic is on the designated list and whether there is an approved treatment plan that covers your condition.
Related terms
- Advanced regenerative medicine
- The Korean legal term for cell, gene and tissue-engineering therapies that use human cells to restore body function or treat disease.
- Designated advanced regenerative medicine institution
- A Korean hospital or clinic designated by the Ministry of Health and Welfare to carry out advanced regenerative medicine.
- Treatment plan review committee
- The Korean government committee that reviews each advanced regenerative medicine research plan and treatment plan before a designated institution may use it.
- Cell therapy product
- A medicine made from living cells that have been cultured, multiplied, selected or otherwise processed outside the body.
Source: Advanced Regenerative Bio Act (Korean, Korea Law Information Center)
Read next
Not sure where to start?
Send your question and any X-ray or MRI report you have. COMEDI, the registered coordinator that runs this guide, replies in writing and can ask a clinic for its written answer and an itemised quote.